Patents by Inventor Vincent Jacques

Vincent Jacques has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HISTONE DEACETYLASE INHIBITORS
    Publication number: 20180208606
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: January 3, 2018
    Publication date: July 26, 2018
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • HDAC inhibitors
    Patent number: 10029988
    Abstract: Disclosed herein are compounds of formula (I), and methods of inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 24, 2018
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche
  • 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME
    Publication number: 20180125827
    Abstract: The invention provides deuterium-enriched thiazolidine-2,4-dione compounds (i.e., deuterium-enriched glitazone compounds), enantiopure forms of deuterium-enriched glitazone compounds, pharmaceutical compositions, and methods of treating compounds, which are preferably in enantiopure form.
    Type: Application
    Filed: September 15, 2017
    Publication date: May 10, 2018
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H.T. van der Ploeg
  • METHODS OF TREATING BACTERIAL INFECTIONS AND FUNGAL INFECTIONS USING ENANTIOPURE DEUTERIUM-ENRICHED PIOGLITAZONE
    Publication number: 20180125834
    Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating bacterial infections and fungal infections using enantiopure deuterium-enriched pioglitazone.
    Type: Application
    Filed: September 15, 2017
    Publication date: May 10, 2018
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H.T. van der Ploeg
  • DEUTERIUM-ENRICHED ISOINDOLINONYL-PIPERIDINONYL CONJUGATES AND OXOQUINAZOLIN-3(4H)-YL-PIPERIDINONYL CONJUGATES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME
    Publication number: 20180118758
    Abstract: The invention provides deuterium-enriched isoindolinonyl-piperidinonyl conjugates, deuterium-enriched oxoquinazolin-3(4H)-yl-piperidinonyl conjugates, pharmaceutical compositions, and methods of using such conjugates and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.
    Type: Application
    Filed: October 13, 2017
    Publication date: May 3, 2018
    Applicants: DeuteRx, LLC, DeuteRx, LLC
    Inventor: Vincent Jacques
  • 5-DEUTERO-THIAZOLIDINYLDIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME
    Publication number: 20180118730
    Abstract: The invention provides deuterium-enriched thiazolidine-2,4-dione compounds (i.e., deuterium-enriched glitazone compounds), enantiopure forms of deuterium-enriched glitazone compounds, pharmaceutical compositions, and methods of treating medical disorders, such as a metabolic disorder, neurological disorders, cancer, or other disorder using deuterium-enriched glitazone compounds, which may be in enantiopure form.
    Type: Application
    Filed: September 15, 2017
    Publication date: May 3, 2018
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • COMBINATION THERAPY USING ENANTIOPURE, OXY-SUBSTITUTED, DEUTERIUM-ENRICHED 5-(BENZYL)-5-DEUTERO-THIAZOLIDINE-2,4-DIONES FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20180117026
    Abstract: The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.
    Type: Application
    Filed: September 15, 2017
    Publication date: May 3, 2018
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H.T. van der Ploeg
  • Histone deacetylase inhibitors
    Patent number: 9908899
    Abstract: The compounds provided herein are phenyl analine amides and are useful for inhibiting histone deacteylase (“HDAC”) enzymes, such as HDAC1, HDAC2, and HDAC3.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: March 6, 2018
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION
    Publication number: 20170369420
    Abstract: The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched bupropion. A preferred aspect of the invention provides methods of treating obesity and sexual dysfunction using enantiopure deuterium-enriched bupropion.
    Type: Application
    Filed: July 11, 2017
    Publication date: December 28, 2017
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H.T. van der Ploeg
  • Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
    Patent number: 9809603
    Abstract: The invention provides deuterium-enriched isoindolinonyl-piperidinonyl conjugates, deuterium-enriched oxoquinazolin-3(4H)-yl-piperidinonyl conjugates, pharmaceutical compositions, and methods of using such conjugates and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: November 7, 2017
    Assignee: DEUTERX, LLC
    Inventor: Vincent Jacques
  • Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
    Patent number: 9732031
    Abstract: The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched bupropion. A preferred aspect of the invention provides methods of treating obesity and sexual dysfunction using enantiopure deuterium-enriched bupropion.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: August 15, 2017
    Assignee: DeuteRx, LLC
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H. T. van der Ploeg
  • HISTONE DEACETYLASE INHIBITORS
    Publication number: 20170050984
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: November 9, 2016
    Publication date: February 23, 2017
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • HISTONE DEACETYLASE INHIBITORS
    Publication number: 20170044186
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Histone deacetylase inhibitors
    Patent number: 9540395
    Abstract: This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: January 10, 2017
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Histone deacetylase inhibitors
    Patent number: 9512143
    Abstract: The compounds provided herein are phenyl analine amides and are useful for inhibiting histone deacteylase (“HDAC”) enzymes, such as HDAC1, HDAC2, and HDAC3.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: December 6, 2016
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • METHODS OF TREATING NEUROLOGICAL, METABOLIC, AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED PIOGLITAZONE
    Publication number: 20160331737
    Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
    Type: Application
    Filed: January 15, 2015
    Publication date: November 17, 2016
    Applicant: DeuteRx, LLC
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H.T. van der Ploeg
  • METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION
    Publication number: 20160311757
    Abstract: The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched bupropion. A preferred aspect of the invention provides methods of treating obesity and sexual dysfunction using enantiopure deuterium-enriched bupropion.
    Type: Application
    Filed: December 19, 2014
    Publication date: October 27, 2016
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H.T. van der Ploeg
  • Methods for collagen imaging
    Patent number: 9386938
    Abstract: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: July 12, 2016
    Assignee: Collagen Medical, LLC
    Inventors: Peter D. Caravan, Andrew Kolodziej, Zhaoda Zhang, Stephane Dumas, Biplab Kumar Das, Vincent Jacques, Richard Looby, Steffi K. Koerner, Wei-Chuan Sun, David R. Buckler, Aida Abujoub, Aaron K. Sato
  • ADENOSINE ANALOGS AND THEIR USE
    Publication number: 20160129036
    Abstract: The invention provides adenosine analog compounds that act at P2Y receptors, e.g., the P2Y2 receptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer.
    Type: Application
    Filed: December 29, 2015
    Publication date: May 12, 2016
    Inventors: EFRAT BEN-ZEEV, VINCENT JACQUES, YAEL MARANTZ, A. SEKAR REDDY, ZHAODA ZHANG, OREN BECKER, DILARA MCCAULEY, PINI ORBACH, SHARON SHACHAM, ASHIS K. SAHA, MICHAEL XIE
  • Adenosine analogs and their use
    Patent number: 9255121
    Abstract: Provided are adenosine analog compounds such as that act as P2Y receptors, e.g., the P2Y2 receptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated with that receptor, e.g., disorders relating to mucus secretion, such as cystic fibrosis, chronic obstructive pulmonary disorder (COPD), asthma, constipation, chronic idiopathic constipation, dry mouth (xerostomia), gum disease, and gastrointestinal problems caused by radiation and chemotherapy for cancer.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: February 9, 2016
    Assignee: MICRODOSE THERAPEUTX, INC.
    Inventors: Efrat Ben-Zeev, Vincent Jacques, Yael Marantz, A. Sekar Reddy, Zhaoda Zhang, Oren Becker, Dilara McCauley, Pini Orbach, Sharon Shacham, Ashis K. Saha, Michael Xie